Advertisement
UK markets closed

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     

  • AIM

    745.67
    +0.38 (+0.05%)
     

  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     

  • GBP/USD

    1.2370
    -0.0068 (-0.55%)
     

  • Bitcoin GBP

    52,025.69
    +611.97 (+1.19%)
     

  • CMC Crypto 200

    1,334.09
    +21.46 (+1.64%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

Mike Lynch-backed Sophia Genetics raises $30 million

Reuters - UK Focus

LONDON, Sept 13 (Reuters) - Sophia Genetics, a data-driven healthcare company backed by British entrepreneur Mike Lynch, has raised $30 million in a funding round led by Balderton Capital (Other OTC: CGHC - news) to further develop its technology.

The company's machine-learning technology analyses DNA (Frankfurt: 24D.F - news) data to help clinicians find the best treatment options for diseases like cancer.

Switzerland-based Sophia said its platform was now being used by 334 hospitals across 53 countries, and had tested more than 125,000 patients to date.

Lynch, who founded and led software firm Autonomy before it was sold to Hewlett Packard (NYSE: HPQ - news) in 2011 in a deal that soured a year later, first invested in Sophia through his Invoke Capital venture capital fund in 2014.

(Reporting by Paul Sandle; editing by Kate Holton)